Scientists at Fox Chase Cancer Center have identified a gene that plays a major role in activating an oncogene, known as MYC, to promote cancer.
The researchers have revealed that the gene identified by them is DLX5, which is crucial for embryonic development.
Breast Cancer during Pregnancy
Management of breast cancer during pregnancy or pregnancy associated breast cancer requires special consideration to avoid harm to the fetus.
Advertisement
They say that the fact that the DLX5 gene is inactive in normal adults indicates that it may be an ideal target for future anti-cancer drugs.
Studies conducted in the past have shown that a chromosomal inversion - a genetic misalignment, where part of the chromosome containing the DLX5 gene gets flipped around during cell division cooperates with another known oncogene, AKT2, to drive cancer in mice.
![Cervical Cancer - Incidence]( "Cervical Cancer - Incidence")
Cervical cancer is the second most common cancer among women and is the primary cause of cancer-related deaths in developing countries
The current study has revealed that DLX5 binds to and actively promotes the activity of a gene known as MYC, which evidence has demonstrated is a potent factor in numerous cancers, including lymphoma, lung and pancreatic cancer.
The experiments behind these findings involved both mouse cancer models and human cell cultures.
"While MYC has a definite role in cancer, MYC also has an important place in the normal functioning of cells, so it may be difficult to target without killing healthy cells. DLX5, however, is not generally active in healthy adult cells, so it represents a much more 'druggable' target for cancer inhibition," says Dr. Joseph Testa, a Fox Chase professor and co-author of the study.
The study, funded by grants from the National Cancer Institute and an appropriation from Commonwealth of Pennsylvania, has been published in the online edition of the Journal of Biological Chemistry.
Source: ANI
TAN
Cervical Cancer - Incidence
Cervical cancer is the second most common cancer among women and is the primary cause of cancer-related deaths in developing countries
Advertisement
The current study has revealed that DLX5 binds to and actively promotes the activity of a gene known as MYC, which evidence has demonstrated is a potent factor in numerous cancers, including lymphoma, lung and pancreatic cancer.
The experiments behind these findings involved both mouse cancer models and human cell cultures.
"While MYC has a definite role in cancer, MYC also has an important place in the normal functioning of cells, so it may be difficult to target without killing healthy cells. DLX5, however, is not generally active in healthy adult cells, so it represents a much more 'druggable' target for cancer inhibition," says Dr. Joseph Testa, a Fox Chase professor and co-author of the study.
The study, funded by grants from the National Cancer Institute and an appropriation from Commonwealth of Pennsylvania, has been published in the online edition of the Journal of Biological Chemistry.
Source: ANI
TAN
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The mission of Axiom Space incorporated numerous experiments focusing on human stem cell aging, inflammation, and cancer within the laboratory situated in the low Earth orbit.
Providing a sustained supply of hydrogen sulfide to cancer cells, could be a remodeling strategy to improve photothermal therapy efficacy while minimizing side effects.
Colon cancer's hidden link revealed in microbiome study.
Breast cancer patients in the obese or overweight category can greatly benefit from a telephone-based weight management program in achieving significant weight loss.
A new study assessed the association of cigarette smoking and vaping on cancer-related symptom burden (fatigue, pain, emotional problems) and quality of life.